PDO MAX INC, a medical device provider for medical aesthetic needs in the United States and Canadian markets, has received 510(k) approval from the US Food and Drug Administration (FDA) for its brand of PDO (polydioxanone) absorbable threads in cannula, it was reported on Friday.
PDO threads are utilised in aesthetic medicine and are a sterile, biodegradable, monofilament synthetic composed polymer. The approval is for both the PDO threads and cannula integrated into one device, unlike many of the other providers in the market.
Juliana Ucchino, vice president of Operations for PDO Max Inc, said, 'We are dedicated to bringing our aesthetic medical professionals, true peace of mind with our FDA cleared PDO threads. PDO MAX threads, used alone, or in addition to the provider's preferred injectable product, greatly add to the ability of our medical professionals to deliver nonsurgical, minimally invasive total facial aesthetics solutions.'
US FDA approves three drugs for non-prescription or over-the-counter use
Epizyme files TAZVERIK NDA under FDA's Priority Review for follicular lymphoma
Elicio Therapeutics, Natera To Collaborate in Phase I/II Pancreatic Cancer Study of ELI-002
INVO Bioscience names new vice president of Medical Affairs
Last Patient Last Visit in Cyclo Therapeutics' Phase I Trial in Niemann-Pick Type C